Prostate cancer

Clinics in Geriatric Medicine

Volumn 13, Issue 2, 1997, Pages 283-306

  Balducci, L ^a   Pow Sang, J ^a   Friedland, J ^a   Diaz, J I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CORTICOSTEROID; CYPROTERONE; DIETHYLSTILBESTROL; ESTRAMUSTINE PHOSPHATE; ESTROGEN DERIVATIVE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; IODINE 125; IRIDIUM 192; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE; NILUTAMIDE; PROGESTERONE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; STRONTIUM 89; SURAMIN;

ADRENAL INSUFFICIENCY; BONE MARROW SUPPRESSION; BONE PAIN; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DRUG COST; EARLY DIAGNOSIS; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEALTH CARE COST; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER TOXICITY; MALE; METASTASIS; NONHUMAN; ORCHIECTOMY; PROSTATE CANCER; PROSTATECTOMY; RADIATION INJURY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0030960470     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0749-0690(18)30170-8     Document Type: Review

References (82)

1. Albertsen P.C. Fryback D.G. Storer B.E. Long-time survival among men with conservatively treated localized prostate cancer JAMA 274 1995 626 631
2. Babaian R.J. Kojima M. Ramirez E.I. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer J Urol 156 1996 432 437
3. Balducci L. Khansur T. Smith T. Prostate cancer: A natural model of cancer in the elderly Arch Gerontol Ger 8 1989 165 187
4. Bubendorf L. Sauter G. Moch H. Prognostic significance of Bcl-2 in clinically localized prostate cancer Am J Pathol 148 1996 1557 1565
5. Bolla M. Gonzalez D. Warde P. Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer: Results of a randomized phase III clinical trial of the European Organization for research and treatment of cancer radiotherapy and urinary tract cancer cooperative groups Proceedings of the American Society of Clinical Oncology 15 1996 238
6. Brawer M.K. Ellis W.J. Chemoprevention for prostate cancer Cancer 75 1995 1783 1789
7. Brawley O.W. Ford L.G. Thompson I. 5-alpha reductase inhibition and prostate cancer prevention Cancer Epidemiol Biomarkers Prev 3 1994 177 182
8. Carter B.S. Bova G.S. Beaty T.H. Hereditary prostate cancer: Epidemiologic and clinical features J Urol 150 1993 797 802
9. Catalona W.J. Smith D.S. Wolfert R.L. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening JAMA 274 1995 1214 1220
10. Catalona W.J. Surgical management of prostate cancer Cancer 75 1995 1903 1908
11. Chauvet B. Felix-Faure C. Lupsascka N. Prostate-specific antigen decline: A major prognostic factor for prostate cancer treated with radiation therapy J Clin Oncol 12 1994 1402 1407
12. Chi S-G. DeVere White R.W. Meyers F.J. p53 in prostate cancer: Frequent expressed transition mutation J Natl Cancer Inst 86 1994 926 933
13. Chodak G.W. Thisted R.A. Gerber G.S. Results of conservative management of clinically localized prostate cancer N Engl J Med 330 1994 242 248
14. Chybowski F.M. Keller J.J.L. Bergstralh E.J. Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters J Urol 145 1991 313 318
15. Colombel M. Symmans F. Gil S. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory prostate cancer Am J Pathol 143 1993 390 400
16. Crawford E.D. Eisenberger M.A. McLeod D.G. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321 1989 419 424
17. D’Amico A.V. Whittington R. Malkowicz S.B. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically confined prostate cancer J Clin Oncol 14 1996 1770 1777
18. D’Amico A.V. Coleman C.N. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: The jury is still out J Clin Oncol 14 1996 304 315
19. Denis L.J. Carneiro De Moura J.L. Bono A. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial Urology 42 1993 119 130
20. diSantagnese P.A. Neuroendocrine differentiation in human prostatic carcinoma Hum Pathol 23 1992 287 296
21. Dorey F. Frankin J. deKernion J. Use of multiple PSA values for predicting clinical disease recurrence after radical retropubic prostatectomy (RPF) [supplement] Proceedings of the American Urological Association 155 1996 487A
22. Dugan J.A. Bostwick D.G. Myers R.P. The definition and preoperative prediction of clinically insignificant prostate cancer JAMA 275 1996 288 294
23. Eisenberger M.A. Crawford E.D. Wolf M. Prognostic factors in stage D2 prostate cancer: Important implications for future trials: Results of a cooperative intergroup study Semin Oncol 21 1994 613 619
24. Eisenberger M.A. Reyno L. Sinibaldi V. The experience with suramin in metastatic prostate cancer Cancer 75 1995 1927 1934
25. Epstein J.I. Pathologic evaluation of prostatic carcinoma: Critical information for the oncologist Oncology 10 1996 527 541
26. Frazier H.A. Robertson J.E. Paulson D.F. Radical prostatectomy: The pros and cons of the perineal versus retropubic prostatectomy J Urol 147 1992 888 890
27. Friedman G.D. Hiatt R.A. Quesenberry G.P. Case-control study of screening for prostatic cancer by digital rectal examination Lancet 337 1991 1526 1529
28. Gann P.H. Hennekens C.H. Stampler M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
29. Garnick M.B. Fair W.R. Prostate Cancer: Emerging Concepts Ann Intern Med 125 1996 118 125
30. Geary E.S. Dendinger T.E. Freiha F.S. Incontinence and vesical neck stricture following radical retropubic prostatectomy Urology 45 1995 1000 1006
31. Gerber G.S. Chodak G.W. Routine screening for cancer of the prostate J Natl Cancer Inst 83 1991 329 338
32. Giovannucci E. Epidemiologic characteristics of prostate cancer Cancer 75 1995 1766 1777
33. Gleason D.S. Mellinger G.T. Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic carcinoma by combined histological grading and clinical staging J Urol 111 1974 58 67
34. Gleave M.E. Goldenberg S.L. Jones E.C. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer J Urol 155 1996 213 219
35. Gohagan J.K. Prorok P.C. Kramer B.S. The prostate, lung, colorectal, and ovarian screening trial of the National Cancer Institute Cancer 75 1995 1869 1873
36. Griffiths K. Eaton C.L. Harper M.E. Hormonal treatment of advanced disease: Some newer aspects Semin Oncol 21 1994 672 687
37. Healy B. Does vasectomy cause prostate cancer? JAMA 269 1993 2620
38. Howards S.S. Peterson H.B. Vasectomy and prostate cancer: Chance, bias, or causal relationship? JAMA 269 1993 913 914
39. Hsing A.W. Devesa S.S. Prostate Cancer Mortality in the United States by Cohort Year of Birth. 1865-1940 Cancer Epidemiol Biomarkers Prev 3 1994 527 530
40. Hussain M. Wolf M. Marshall E. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report J Clin Oncol 12 1994 1868 1875
41. Isaacs W.B. Bova G.S. Morton R.A. Molecular biology of prostate cancer Semin Oncol 21 1994 514 521
42. Jacobsen S.J. Katusic S.K. Bergstrahl E.J. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing JAMA 274 1995 1445 1449
43. Janknegt R.A. Abbou C.C. Bartoletti R. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial J Urol 149 1993 77 83
44. Koch M.O. Smith J.A. Influence of patient age and comorbidity on outcome of a collaborative care pathway after radical prostatectomy and cystoprostatectomy J Urol 155 1996 1681 1684
45. Kreis W. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer Cancer Invest 13 1995 296 312
46. Lee W.R. Hanlon A.L. Hanks G.E. Prostate specific antigen nadir following external beam irradiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival J Urol 156 1996 450 453
47. Litwin M.S. Hays R.D. Fink A. Quality-of-life outcomes in men treated for localized prostate cancer JAMA 273 1995 129 135
48. Madsen P.O. Graversen P.H. Gasser T.C. Treatment of localized prostatic cancer. Radical prostatectomy vs placebo: A 15 year follow-up Scand J Urol Nephrol 110 Suppl 1988 95 100
49. Mebane C. Gibbs T. Horm J. Current status of prostate cancer in North American black males J Natl Med Assoc 82 1990 782 789
50. Mettlin C. Murphy J.P. Babaian R.J. The results of a five year early prostate cancer detection intervention Cancer 77 1996 150 159
51. Mora L. Nicosia S. Ku N. Ancillary techniques in the follow-up of transitional cell carcinoma: A comparison of cytology, histology, and DNA image analysis cytometry in 91 patients J Urol 156 1996 49 55
52. Morgan T.O. Jacobsen S.J. McCarthy W.F. Age-specific reference ranges for serum prostate-specific antigen in black men N Engl J Med 335 1996 304 310
53. Oesterling J.E. Prostate Specific Antigen: Its role in the diagnosis and staging of prostate cancer Cancer 75 1995 1795 1804
54. Oesterling J.E. Martin S.K. Bergstralh E.J. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer JAMA 269 1993 57 60
55. Parker S.L. Tong T. Bolden S. Cancer Statistics, 1996 CA Cancer J Clin 46 1996 5 43
56. Pilepich M.V. Krall J.M. Al-Sarraf M. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the radiation therapy oncology group Urology 45 1995 616 623
57. A.T. Porter E. Ben-Josef Strontium-89 in the treatment of bony metastases DeVita V.T. Hellman S. Rosenberg S.A. Important Advances in Oncology, 1995 1995 J B Lippincott Philadelphia 87 94
58. Potosky A.L. Miller B.A. Albertsen P.C. The role of increasing detection in the rising incidence of prostate cancer JAMA 273 1995 548 552
59. Prestigiacomo A.F. Lilja H. Petrsson K. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: The best case scenario J Urol 156 1996 350 354
60. Prostate Cancer trialists Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients Lancet 346 1995 265 269
61. Rees M.A. Campbell S.C. Klein E.A. Validation of a model for prediciting metastatic disease in the pelvic lymph nodes of patients with clinically localized prostate cancer [supplement] Proceedings of the American Urological Association 155 1996 487A
62. Robinson R. Preston D.F. Schiefelbein M. Strontium 89 therapy for the palliation of pain due to osseous metastases JAMA 274 1995 420 424
63. Ruckle H.C. Klee G.G. Oesterling J.E. Prostate-specific antigen: Critical issues for the practicing physician Mayo Clin Proc 69 1994 59 68
64. Ruckle H.C. Klee G.G. Oesterling J.E. Prostate specific antigen: Concepts for staging prostate cancer and monitoring response to therapy Mayo Clin Proc 69 1994 69 79
65. Sartor O. Cooper M. Weinberger M. Surprising activity of flutamide withdrawal when combined with aminoglutethimide in treatment of hormone-refractory prostate cancer J Natl Cancer Inst 86 1994 222 227
66. Scardino P.T. Problem of prostate cancer J Urol 152 1994 1677 1684
67. Scher H.I. Zhang Z.F. Nanus D. Hormone and antihormone withdrawal: Implications for the management of androgen-independent prostate cancer Urology 47 1996 61 69
68. Schwartz B.R. Pinkus G. Bacus S. Cell proliferation in non-Hodgkin’s lymphomas Am J Pathol 134 1989 327 336
69. Smitt M.C. Heltzel M. The results of radical prostatectomy at a community hospital during the prostate specific antigen era Cancer 77 1996 928 933
70. Spitz Familial patterns of prostate cancer: A case-control analysis J Urol 146 1991 1305 1310
71. Stamey T.A. Ekman P.E. Blankenstein M.A. Tumor markers: Consensus conference on diagnosis and prognostic parameters in localized prostate cancer Scand J Urol Nephrol 162 1994 73 87
72. Steinberg G.D. Carter B.S. Beaty T.H. Family history and the risk of prostate cancer The Prostate 17 1990 337 347
73. Stock R. Locoregional therapies for early-stage prostate cancer Oncology 9 1995 803 815
74. Talcott J.A. Rieker P. Propert K.J. Long-term complications of treatment for early prostate cancer: 2-year follow-up in a prospective multiinstitutional outcomes study Proceedings of the American Society of Clinical Oncology 15 1996 252
75. Tannock I.F. Osoba D. Stockier M.R. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
76. Taylor C.D. Elson P. Trump D.L. Importance of continued testicular suppression in hor-mone-refractory prostate cancer J Clin Oncol 11 1993 2167 2172
77. Walsh P.C. Lepor H. Eggleston J.C. Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations Prostate 4 1983 473 485
78. Woolf S.H. Screening for prostate cancer with prostate-specific antigen N Engl J Med 333 1995 1401 1405
79. WU J.J. King S.C. Montana G.S. The efficacy of post-prostatectomy radiotherapy in patients with an isolated elevation of serum prostate specific antigen Int J Rad Oncol Biol Phys 32 1995 317 323
80. Zacharia B. Casey L. Balducci L. Radiation therapy of the oldest old cancer patient: A study of effectiveness and toxicity J Am Geriatr Soc 43 1995 1 3
81. Zelefsky M.J. Leibel S.A. Burman C.M. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three dimensional conformal radiation therapy Int J Radiat Oncol 29 1994 755 761
82. Zelefsky M.J. Leibel S.J. Wallner K.E. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer J Clin Oncol 13 1995 459 463